Some Med Spas Sell Weight-Loss Drugs From Questioned Pharmacies

Mirage News Mirage News Mirage News Health 18 Jul 2026 1:06 am AEST Date Time CU Anschutz researchers found the compounded GLP-1 market remains robust after FDA shortages ended, with some products supplied by pharmacies lacking sterile compounding licenses or with recent disciplinary histories Despite the end of federal shortages of popular GLP-1 weight-loss medications, the market for compounded alternatives remains strong - and some patients may unknowingly be receiving products from pharmacies with concerning regulatory histories, according to new research from the University of Colorado Anschutz.

Published today in JAMA Health Forum, the study found that many weight-loss clinics and medical spas continue to sell compounded versions of GLP-1 medications such as semaglutide and tirzepatide.

Researchers also identified suppliers that lacked licenses required for sterile compounding or had recently been subject to disciplinary actions related to sterile compounding practices.

"Our findings suggest this market didn't shrink after the shortages ended as many expected," said lead author Michael J.

DiStefano, PhD, MBE, assistant professor at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences.

"Instead, it has remained remarkably robust, raising important questions about how these products are regulated and how patients can know whether they're receiving medications that meet appropriate quality standards." Compounded GLP-1 drugs expanded rapidly during nationwide shortages of Wegovy and Zepbound, when federal regulations temporarily allowed pharmacies to compound copies of medications in short supply.

Researchers wanted to know what happened after those shortages ended and the FDA resumed enforcement against routine copies of commercially available products.

DiStefano and colleagues examined brick-and-mortar weight-loss clinics and medical spas, an area that has received less scrutiny than online telehealth despite serving many patients.

Using a "secret shopper" approach, researchers contacted businesses in Oklahoma and West Virginia to ask what products were available, how patients were monitored and where the medications were sourced.

The team identified 75 clinics and medical spas offering compounded GLP-1 medications.

Instead of seeing the market disappear, the researchers found evidence that many compounded products now include added ingredients, such as vitamin B12, which may be presented as individualized formulations.

"One concern is whether we're seeing clinically meaningful personalization or changes that primarily allow compounded products to remain on the market," DiStefano said.

"For many of these added ingredients, we simply don't have good evidence showing they improve safety or effectiveness." Additionally, among the 23 compounding pharmacies supplying these businesses, four lacked licenses for sterile compounding, while several had recent disciplinary actions or FDA warning letters related to sterile compounding practices.

DiStefano emphasized that compounded GLP-1 medications have helped expand access for patients who cannot afford brand-name drugs or whose insurance does not cover obesity treatment.

However, he said patients should not have to choose between affordability and quality.

"This market has grown so large and diffuse that it's difficult for regulators to oversee every pharmacy supplying these medications," he said.

"Our findings suggest there's a need for regulatory innovation that preserves access while giving patients greater confidence that the products they're receiving are safe and appropriately manufactured." The researchers hope the findings encourage clinicians and patients to ask more questions about where compounded medications originate and whether the pharmacies producing them meet appropriate standards for sterile compounding.

/Public Release.

This material from the originating organization/author s might be of the point-in-time nature, and edited for clarity, style and length.

Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author s .View in full here.

Why?

Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests.

We don't put up a paywall – we believe in free access to information of public interest.

Media ownership in Australia is one of the most concentrated in the world Learn more .

Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country.

According to independent assessment, about 98% of the media sector is held by three conglomerates.

This tendency is not only totally unacceptable, but also to a degree frightening .

Learn more here We endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources.

It is a bumpy road with all sorties of difficulties.

We can only achieve this goal together.

Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information.

You and we have the right to know, learn, read, hear what and how we deem appropriate.

Your support is greatly appreciated.

All donations are kept completely private and confidential.

Thank you in advance

Tags: health , university , research , West Virginia , insurance , treatment , Colorado , FDA , Virginia , Professor , Oklahoma , pharmacy , affordability , innovation , telehealth , CU Anschutz , clinicians

Peptides referenced: Semaglutide, Tirzepatide, GLP-1.